Drug allergy (DA) remains a complex and unaddressed problem worldwide that often
deprives patients of optimal medication choices and places them at risk for life‐threatening …

Drug-induced hypersensitivity syndrome (DiHS), also known as drug reaction with
eosinophilia and systemic symptoms (DRESS), is a severe cutaneous adverse reaction …

Background Immune-related adverse events due to immune checkpoint inhibitors (ICIs) are
not always effectively treated using glucocorticoids and it may negatively affect the antitumor …

Drug reaction with eosinophilia and systemic symptoms or drug-induced hypersensitivity
syndrome (DRESS/DIHS) is one type of severe cutaneous adverse reaction (SCAR). It is …

Immune‐mediated type IV adverse drug reactions are idiosyncratic in nature, generally not
related to the primary or secondary pharmacology of the drug. Due to their complex nature …

Drug hypersensitivity reactions (DHRs) are type B adverse drug reactions (ADRs)
traditionally defined as unpredictable, dose independent and not related to the drug …

Pharmacogenomics aims to understand how genetic variation influences drug response.
This understanding has the potential to support clinicians to deliver personalized therapy …

Drugs can activate different cells of the immune system and initiate an immune response
that can lead to life-threatening diseases collectively known as severe cutaneous adverse …

Definition of the relationship between drug protein adduct formation (haptenation) and
development of immunological adverse drug reactions (drug hypersensitivity) has been an …

The introduction of immune checkpoint inhibitors (ICIs) has transformed the management of
various malignancies. Alongside their therapeutic success, the widespread application of …